BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

My pharma company 2.0 would be focussed around three core operating units – therapeutic area interventions, product development and central operations. Therapeutic area interventions ...

In 2019, the pharmaceutical ... (CO 2 e) for every $1m it generated – placing it above even the automotive industry, which emitted 31.4 tons per $1m generated in the same year, in terms of ...

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

Companies that have grown profits and net profit margins over the past 12 months ...

Sunil Subramaniam, a market expert, remains optimistic about the long-term prospects of the IT and pharmaceutical sectors due ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

They include OTC Brand of the Year; Pharmacy Only/POM Brand of the Year; Most Outstanding Export-oriented Pharma Manufacturer of the Year and Pharma Multinational Company of the Year. Entries for ...

Bayer’s Crop Sciences division holds significant potential despite glyphosate issues. See why BAYRY stock is undervalued and ...

Avoiding a second trial, a former pharmaceutical rep who prosecutors said generated more than $10 million in wrongful insurance reimbursements pleaded guilty Tuesday to perjury in U.S. District Court.

During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical ... least 2038. Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results ...